CAI Launches Next Chapter with Investment from JLL Partners
INDIANAPOLIS, May 5, 2026 – CAI, a professional services firm dedicated to accelerating operational readiness and excellence in life sciences and mission-critical environments, today announced that it has entered into...
Read MoreAdvancing CQV: What the Latest ISPE Baseline® Guide Volume 5 Addendum and ASTM E2500-2025 Mean for the Industry
The release of the ISPE Baseline® Guide Volume 5 (Second Edition) QRM Addendum- C&Q Delivery Process and ASTM E2500-2025 marks a significant step forward for...
Read MoreThe Hidden Constraint in GMP Operations Decision-making: Data Friction, Not Decision Quality
Biopharma manufacturing has never had more data than it does today, yet decision making has never felt slower, riskier, or more burdened by uncertainty. Every choice in a...
Read MoreThe Pillars of Readiness: Building Toward Day One Success
Operational readiness isn’t a milestone. It’s a condition, a designed state that ensures your facility starts up safely, on time, on budget, and at the...
Read MoreCAI Marks Thirty Years Advancing Operational Readiness and Excellence Across Life Sciences and Mission-Critical Industries
From CQV roots to a broader operational readiness model, CAI continues helping organizations navigate rising complexity and operate with confidence and speed in highly regulated...
Read MoreThe Hidden Constraint in GMP Operations Decision-making: Data Friction, Not Decision Quality
Biopharma manufacturing has never had more data than it does today, yet decision making has never felt slower, riskier, or more burdened by uncertainty. Every choice in a...
Read MoreThirty Years of Readiness: What Three Decades in Regulated Industries Have Really Taught Us
When I founded Commissioning Agents in 1996, the practice of “validation” was a paperwork exercise that was ineffective at assuring equipment worked to meet stakeholder...
Read MoreA Commentary on the Draft EMA Annex 15 Changes in the Context of The CAI OR Program
Why the EMA Annex 15 Concept Paper Signals a Shift—and How It Aligns with The CAI Six Pillars of Operational Readiness In Feb 2026 the EMA with...
Read MoreBeyond Batch Testing: What FDA’s Draft Guidance on 21 CFR 211.110 Signals for the Future of Pharmaceutical Manufacturing
How evolving inspection expectations, digital manufacturing, and AI-enabled quality systems are reshaping pharmaceutical control strategies. For many pharmaceutical organizations, the FDA’s draft guidance on Considerations for Complying with 21...
Read More